LitCovid-sentences  

PMC:7200337 / 75252-78559 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T424 0-25 Sentence denotes Antiviral Clinical Trials
T425 26-118 Sentence denotes A large number of clinical trials using experimental antiviral drugs are currently underway.
T426 119-480 Sentence denotes A small proportion of them are aimed at repurposing existing antivirals, including arbidol (umifenovir), a broad-spectrum antiviral that blocks viral fusion; lopinavir/ritonavir (LPV/r), a combination of anti-HIV protease inhibitors; favipiravir, an RdRp inhibitor used to treat severe influenza infections (Hayden and Shindo, 2019); and remdesivir (Figure 6A).
T427 481-646 Sentence denotes Chen et al. conducted a multicenter, randomized priority trial on 240 patients with confirmed COVID-19 infection to test favipiravir or arbidol (Chen et al., 2020b).
T428 647-713 Sentence denotes Favipiravir was suggested to significantly improve symptom relief.
T429 714-896 Sentence denotes However, the interpretation of this study is limited by a short clinical recovery window of 7 days, only 100 of 236 patients with confirmed COVID-19, and the lack of a control group.
T430 897-1040 Sentence denotes LPV/r has previously shown efficacy in treating SARS-Cov-1 (Chu et al., 2004), prompting an early SARS-Cov-2 clinical trial (Li et al., 2020c).
T431 1041-1224 Sentence denotes 44 patients were enrolled in a trial investigating the efficacy and safety of LPV/r (n = 21 patients), arbidol (n = 16), or control (n = 7) as treatment for mild to moderate COVID-19.
T432 1225-1428 Sentence denotes At day 14 of treatment, 76.2%, 62.4%, and 71.4% of patients had a positive to negative conversion in the LPV/r, arbidol, and control groups, respectively, with no statistical significance between groups.
T433 1429-1573 Sentence denotes A randomized controlled trial (RCT) with 200 severe COVID-19 patients did not observe a significant benefit of LPV/r either (Cao et al., 2020a).
T434 1574-1793 Sentence denotes However, a study that looked at the impact of earlier administration of LPV/r treatment showed that when treatment of LPV/r was started within 10 days of symptom onset, a shorter duration of virus shedding was observed.
T435 1794-1883 Sentence denotes Thus, timing of LPV/r administration may be critical to its efficacy (Yan et al., 2020a).
T436 1884-2090 Sentence denotes In a multicenter clinical study assessing the compassionate use of remdesivir in severe COVID-19 patients, 53 patients across several countries were treated with remdesivir for 10 days (Grein et al., 2020).
T437 2091-2222 Sentence denotes 68% of the 53 patients who received remdesivir showed clinical improvement assessed through improved oxygen support or extubations.
T438 2223-2347 Sentence denotes Without a proper control group, limited conclusions can be drawn with regards to the efficacy of remdesivir from this study.
T439 2348-2500 Sentence denotes The measured 68% clinical improvement may be in line with average clinical improvement across patients treated with standard of care (Li et al., 2020c).
T440 2501-2689 Sentence denotes A small RCT in China with 237 severe COVID-19 patients randomized 2:1 to remdesivir versus placebo demonstrated no significant benefit in time to clinical improvement (Wang et al., 2020g).
T441 2690-2921 Sentence denotes Almost simultaneously, preliminary results from a larger National Institute of Allergy and Infectious Diseases (NIAID) RCT with more than 1,000 patients were announced with remdesevir to be associated with quicker time to recovery:
T442 2922-2968 Sentence denotes 11 days compared with 15 days (Ledford, 2020).
T443 2969-3105 Sentence denotes A non-significant benefit in mortality was also noted, and the trial was stopped early to allow access to remdesivir in the placebo arm.
T444 3106-3307 Sentence denotes Complete safety data and full publication are awaited, but this study offers encouraging results and has resulted in an FDA emergency use authorization for remdesivir in hospitalized COVID-19 patients.